| Business Summary | | Carrington
Laboratories,
Inc.
is
a
research-based
biopharmaceutical,
medical
device
and
raw
materials
and
nutraceutical
company
engaged
in
the
development,
manufacturing
and
marketing
of
naturally
derived
complex
carbohydrates
and
other
natural
product
therapeutics
for
the
treatment
of
major
illnesses,
the
dressing
and
management
of
wounds
and
nutritional
supplements.
The
Company
is
comprised
of
two
business
segments.
The
Company
sells
prescription
and
nonprescription
human
and
veterinary
products
through
its
Medical
Services
Division
and
consumer
and
bulk
raw
material
products
through
its
consumer
products
subsidiary,
Caraloe,
Inc. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | CARN
is
a
research-based
pharmaceutical
and
medical
device
company
engaged
in
the
development,
manufacturing
and
marketing
of
naturally
derived
complex
carbohydrate
and
other
natural
product
therapeutics
for
the
treatment
of
illnesses
and
wounds.
For
the
six
months
ended
6/30/01
sales
fell
29%
to
$9
million.
Net
income
totalled
$286
thousand,
vs.
a
loss
of
$1.2
million.
Revenues
reflect
lower
sales
from
Caraloe.
Earnings
reflect
lower
S/G/A
costs
and
the
absence
of
clinical
trials. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| George DeMott, 68 Chairman | -- | Carlton Turner, Ph.D., 60 Pres
and CEO | $306K | Robert Schnitzius, 43 CFO
and Treasurer and Sec. | 153K | G. Scott Vogel, 56 VP-Operations | -- | Kenneth Yates, 50 VP
of Research and Devel. | 147K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|